Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Complete Molecular Response”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Post-approval studies (Phase 4)Study completedNCT00171899
What this trial is testing

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 80
Large-scale testing (Phase 3)Study completedNCT00760877
What this trial is testing

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

Who this might be right for
CHRONIC MYELOGENOUS LEUKEMIA
Novartis Pharmaceuticals 207
Not applicableNot Yet RecruitingNCT07799337
What this trial is testing

IRELAND Trial: A Translational Biomarker and Exercise Study During Neoadjuvant Breast Cancer Therapy

Who this might be right for
Breast NeoplasmsBreast Cancer
National University of Ireland, Galway, Ireland 250
Post-approval studies (Phase 4)Study completedNCT01243489
What this trial is testing

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation

Who this might be right for
Chronic Myelogenous Leukemia (CML)
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 104
Post-approval studies (Phase 4)Study completedNCT01227577
What this trial is testing

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Who this might be right for
Chronic Myelogenous Leukemia in Chronic Phase
Novartis Pharmaceuticals 128
Testing effectiveness (Phase 2)Study completedNCT01850004
What this trial is testing

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

Who this might be right for
Chronic Phase Chronic Myeloid Leukemia
Bristol-Myers Squibb 84
Not applicableLooking for participantsNCT02306096
What this trial is testing

Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer

Who this might be right for
Breast Neoplasms
Lund University 20,000
Not applicableUnknownNCT01564836
What this trial is testing

Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib

Who this might be right for
Chronic Myeloid LeukemiaImatinibComplete Molecular Response
Seoul St. Mary's Hospital 50
Not applicableNot Yet RecruitingNCT07799649
What this trial is testing

CtDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 150
Testing effectiveness (Phase 2)UnknownNCT01887561
What this trial is testing

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Who this might be right for
Myelogenous Leukemia, Chronic, Chronic Phase
Kanto CML Study Group 100
Large-scale testing (Phase 3)Ended earlyNCT01827930
What this trial is testing

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response

Who this might be right for
Leukemia, Myeloid, Chronic-Phase
Institut Bergonié 68
Testing effectiveness (Phase 2)Ended earlyNCT00415857
What this trial is testing

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 5
Testing effectiveness (Phase 2)Ended earlyNCT01570868
What this trial is testing

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 51
Large-scale testing (Phase 3)Study completedNCT01535391
What this trial is testing

Nilotinib in PH+, BCR-, ABL+ CML Patients

Who this might be right for
Chronic Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 109
Post-approval studies (Phase 4)Study completedNCT01735955
What this trial is testing

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Who this might be right for
Chronic Myelogenous Leukemia (CML)Metastatic Gastrointestinal Stromal Tumors (GIST)Acute Lymphoblastic Leukemia (ALL)+1 more
Novartis Pharmaceuticals 57
Not applicableEnded earlyNCT01073436
What this trial is testing

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Who this might be right for
Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center 7
Early research (Phase 1)Study completedNCT01933906
What this trial is testing

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Who this might be right for
Chronic Phase Chronic Myeloid Leukemia
Arbeitsgemeinschaft medikamentoese Tumortherapie 12
Testing effectiveness (Phase 2)Study completedNCT00005780
What this trial is testing

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

Who this might be right for
Mantle Cell LymphomaLymphoma, Mantle Cell
National Cancer Institute (NCI) 26
Not applicableStudy completedNCT03540654
What this trial is testing

Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach

Who this might be right for
Hematologic DiseasesChronic Myeloid Leukemia
University Hospital, Bordeaux 355
Not applicableLooking for participantsNCT06744465
What this trial is testing

NearWave Optical Molecular Monitoring

Who this might be right for
Breast CancerHER2-positive Breast CancerTNBC - Triple-Negative Breast Cancer+2 more
Indiana University 15
Next Page